Genetic insights into thymic carcinomas and thymic neuroendocrine neoplasms denote prognosis signatures and pathways.
Journal
Chinese medical journal
ISSN: 2542-5641
Titre abrégé: Chin Med J (Engl)
Pays: China
ID NLM: 7513795
Informations de publication
Date de publication:
20 Nov 2023
20 Nov 2023
Historique:
received:
10
04
2023
medline:
30
11
2023
pubmed:
26
9
2023
entrez:
26
9
2023
Statut:
ppublish
Résumé
Thymic carcinomas (TCs) and thymic neuroendocrine neoplasms (TNENs) are two aggressive subtypes of thymic malignancy. Traditional therapy for advanced TCs and TNENs has limited outcome. New genomic profiling of TCs and TNENs might provide insights that contribute to the development of new treatment approaches. We used gene panel sequencing technologies to investigate the genetic aberrations of 32 TC patients and 15 TNEN patients who underwent surgery at Shanghai Chest Hospital between 2015 and 2017. Patient samples were sequenced using a 324-gene platform with licensed technologies. In this study, we focused on clinically relevant genomic alterations (CRGAs), which are previously proven to be pathogenic alterations, to identify the pathology-specific mutational patterns, prognostic signatures of TCs and TNENs. The mutational profiles between TCs and TNENs were diverse. The genetic alterations that ranked highest in TCs were in CDKN2A, TP53, ASXL1, CDKN2B, PIK3C2G, PTCH1, and ROS1 , while those in TNENs were in MEN1, MLL2, APC, RB1 , and TSC2 . Prognostic analysis showed that mutations of ROS1, CDKN2A, CDKN2B, BRAF, and BAP1 were significantly associated with worse outcomes in TC patients, and that mutation of ERBB2 indicated shortened disease-free survival (DFS) and overall survival (OS) in TNEN patients. Further investigation found that the prognosis-related genes were focused on signal pathways of cell cycle control, chromatin remodeling/DNA methylation, phosphoinositide 3-kinases (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR), and receptor tyrosine kinase (RTK)/RAS/mitogen-activated protein kinase (MAPK) signaling. We profiled the mutational features of 47 Chinese patients with thymic malignancy of diverse pathologic phenotypes to uncover the integrated genomic landscape of these rare tumors, and identified the pathology-specific mutational patterns, prognostic signatures, and potential therapeutic targets for TCs and TNENs.
Sections du résumé
BACKGROUND
BACKGROUND
Thymic carcinomas (TCs) and thymic neuroendocrine neoplasms (TNENs) are two aggressive subtypes of thymic malignancy. Traditional therapy for advanced TCs and TNENs has limited outcome. New genomic profiling of TCs and TNENs might provide insights that contribute to the development of new treatment approaches.
METHODS
METHODS
We used gene panel sequencing technologies to investigate the genetic aberrations of 32 TC patients and 15 TNEN patients who underwent surgery at Shanghai Chest Hospital between 2015 and 2017. Patient samples were sequenced using a 324-gene platform with licensed technologies. In this study, we focused on clinically relevant genomic alterations (CRGAs), which are previously proven to be pathogenic alterations, to identify the pathology-specific mutational patterns, prognostic signatures of TCs and TNENs.
RESULTS
RESULTS
The mutational profiles between TCs and TNENs were diverse. The genetic alterations that ranked highest in TCs were in CDKN2A, TP53, ASXL1, CDKN2B, PIK3C2G, PTCH1, and ROS1 , while those in TNENs were in MEN1, MLL2, APC, RB1 , and TSC2 . Prognostic analysis showed that mutations of ROS1, CDKN2A, CDKN2B, BRAF, and BAP1 were significantly associated with worse outcomes in TC patients, and that mutation of ERBB2 indicated shortened disease-free survival (DFS) and overall survival (OS) in TNEN patients. Further investigation found that the prognosis-related genes were focused on signal pathways of cell cycle control, chromatin remodeling/DNA methylation, phosphoinositide 3-kinases (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR), and receptor tyrosine kinase (RTK)/RAS/mitogen-activated protein kinase (MAPK) signaling.
CONCLUSION
CONCLUSIONS
We profiled the mutational features of 47 Chinese patients with thymic malignancy of diverse pathologic phenotypes to uncover the integrated genomic landscape of these rare tumors, and identified the pathology-specific mutational patterns, prognostic signatures, and potential therapeutic targets for TCs and TNENs.
Identifiants
pubmed: 37749819
doi: 10.1097/CM9.0000000000002852
pii: 00029330-990000000-00812
pmc: PMC10684125
doi:
Substances chimiques
Protein-Tyrosine Kinases
EC 2.7.10.1
Proto-Oncogene Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2712-2721Informations de copyright
Copyright © 2023 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.
Références
J Thorac Oncol. 2019 Aug;14(8):1472-1483
pubmed: 31042566
Cell Death Dis. 2012 Jul 19;3:e351
pubmed: 22825469
Eur J Cardiothorac Surg. 2016 Oct;50(4):766-771
pubmed: 27032473
Hum Mol Genet. 1995 Oct;4(10):1883-7
pubmed: 8595411
J Clin Oncol. 2011 Dec 20;29(36):4820-7
pubmed: 22105817
J Thorac Oncol. 2015 Feb;10(2):373-80
pubmed: 25299233
Mod Pathol. 2001 Oct;14(10):985-94
pubmed: 11598168
J Thorac Oncol. 2022 Jun;17(6):827-837
pubmed: 35158083
Cell. 2018 Apr 5;173(2):321-337.e10
pubmed: 29625050
Exp Ther Med. 2022 Feb;23(2):114
pubmed: 34970337
J Thorac Oncol. 2018 Sep;13(9):1373-1382
pubmed: 29883837
Ann N Y Acad Sci. 2004 Apr;1014:189-98
pubmed: 15153434
Clin Cancer Res. 2021 Dec 15;27(24):6662-6665
pubmed: 34580112
J Thorac Oncol. 2015 Oct;10(10):1383-95
pubmed: 26295375
Hematol Oncol Clin North Am. 2008 Jun;22(3):393-407
pubmed: 18514123
Neuroendocrinology. 2017;105(2):105-114
pubmed: 28355610
Int J Mol Sci. 2021 Jan 03;22(1):
pubmed: 33401599
Hematol Oncol Clin North Am. 2008 Jun;22(3):443-55
pubmed: 18514126
J Clin Oncol. 2017 Aug 10;35(23):2613-2618
pubmed: 28520527
Ann Thorac Surg. 2002 Apr;73(4):1076-81
pubmed: 11996244
J Thorac Cardiovasc Surg. 2015 Jan;149(1):95-100, 101.e1-2
pubmed: 25524678
Cancer Genet Cytogenet. 2003 Oct 1;146(1):66-9
pubmed: 14499698
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
Mol Cell Biol. 2009 Sep;29(18):5060-9
pubmed: 19596783
Cell Res. 2015 Nov;25(11):1205-18
pubmed: 26470845
Lung Cancer. 2013 Mar;79(3):289-93
pubmed: 23286964
Cancer Cell. 2018 Feb 12;33(2):244-258.e10
pubmed: 29438696
Sci Rep. 2014 Dec 08;4:7336
pubmed: 25482724
Ecancermedicalscience. 2019 Jan 29;13:900
pubmed: 30915158
Genes Chromosomes Cancer. 2014 Sep;53(9):738-49
pubmed: 24764238
Am J Clin Pathol. 2000 Jul;114(1):100-10
pubmed: 10884805
J Thorac Oncol. 2014 Aug;9(8):1171-9
pubmed: 25157770
J Clin Oncol. 2004 Jan 15;22(2):293-9
pubmed: 14722038
Ann Surg. 2010 Jun;251(6):1117-21
pubmed: 20485130
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
J Thorac Oncol. 2010 Oct;5(10 Suppl 4):S260-5
pubmed: 20859116
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Ann Thorac Surg. 2013 Sep;96(3):1019-24
pubmed: 23866799
Thorac Cancer. 2018 Dec;9(12):1603-1613
pubmed: 30276969
Pathol Oncol Res. 2017 Jul;23(3):551-564
pubmed: 27844328
Eur J Cardiothorac Surg. 2019 Apr 1;55(4):601-609
pubmed: 30649256
Biomarkers. 2019 Nov;24(7):700-711
pubmed: 31382782
J Control Release. 2010 Sep 15;146(3):264-75
pubmed: 20385184
Crit Rev Oncol Hematol. 2016 Mar;99:332-50
pubmed: 26818050
Ann Oncol. 2019 Jul 1;30(7):1121-1126
pubmed: 30980071
J Thorac Oncol. 2017 May;12(5):860-871
pubmed: 28179162
Ann Thorac Cardiovasc Surg. 1999 Oct;5(5):285-92
pubmed: 10550713
Cancer. 1981 Dec 1;48(11):2485-92
pubmed: 7296496
Lancet Oncol. 2019 Dec;20(12):1691-1701
pubmed: 31669155
PLoS One. 2013 Jul 24;8(7):e66047
pubmed: 23894276
Genes Chromosomes Cancer. 1998 Jul;22(3):232-40
pubmed: 9624535
J Thorac Cardiovasc Surg. 2015 Jan;149(1):103-9.e2
pubmed: 25308116